January 29, 2018
Sanofi buys Ablynx for €3,9 billion
Sanofi will buy Belgian Nanobody technology specialist Ablynx for €3.9 billion, it was announced Monday by both companies.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: M&A
January 8, 2018
Calgene Corp buys Impact Biomedicines for $2,3 billion
Celgene Corporation and Impact Biomedicines have agreed for Celgene to acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and…
January 8, 2018
Novo Nordisk in Ablynx €2.6 Billion buy
Novo Nordisk on Monday confirmed proposing on December 22, 2017 to acquire Ablynx for €28.00 per share in cash and…
August 28, 2017
Sanofi buys US-based Protein Sciences
Sanofi has acquired USA based Protein Sciences, a vaccines biotechnology company located in Meriden, Connecticut. The Federal Trade Commission’s approval…
March 6, 2017
TiGenix waits for final EMA nod for its Crohn’s disease drug
TiGenix has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Crohn’s disease drug Cx601 in 2017.
January 20, 2017
Sanofi’s M&A misses frustrate some investors in drugmaker
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
December 30, 2016
Corporate makeovers drive corporate takeovers in 2016 M&A bonanza
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.